Written By: Pharmacally Medical News Desk AstraZenecas investigational oral GLP1 receptor agonist elecoglipron (AZD5004) is advancing toward Phase III development, supported by positive Phase IIb data in both type 2 diabetes and chronic weight management as outlined in the companys FY 2025 Clinical Trials Appendix
What it sees as a kilogram of lean tissue gain after a heavy training block with full glycogen stores is not a kilogram of new contractile protein, any more than what it sees as a kilogram of lean tissue loss on a GLP-1 is a kilogram of departed muscle
These discrepancies most likely stem from variations in the disease stage, therapy length, dosage and formulation of supplements, geographic iodine availability, and baseline nutritional status
Complete biotransformation and protection from oxidative stress are important to maintaining cellular integrity and tissue health
THE RISE OF MICRODOSING WHILE THE GLP-1 microdosing tipping point for Turner was his wifes experience, for many other health-optimizing-curious guys it was an October 2024 episode of Huberman Lab
